{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-015159","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.560362+00:00","generated_at":"2026-05-15T19:52:30.853612+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed","bullets":["Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.","Cash and equivalents $262.9M; cash runway projected through mid-2029.","Initiated dosing in PROPEL-IPF Phase 2 trial of PIPE-791 for IPF (324 patients).","Amended ATM sales agreement to offer up to $100M in common stock; lock-up until March 11, 2026.","Topline data from PIPE-791 Phase 1b chronic pain trial expected Q2 2026; J&J Phase 2 MDD trial recruiting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-015159","json":"https://secwatch.observer/filing/0001628280-26-015159.json","markdown":"https://secwatch.observer/filing/0001628280-26-015159.md","text":"https://secwatch.observer/filing/0001628280-26-015159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/0001628280-26-015159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/ctnm-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:52:30.853612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}